Pharma Case Interview: Drug Launch, Pipeline Valuation, and Pricing Strategy (2026)

A pharma case interview in 2026 asks you to price or forecast a drug the way a life-sciences consulting team actually would: anchor the price to the incremental clinical value over the standard-of-care comparator (a cost-per-QALY logic), not to the cost of making the pill. That is what makes it one of the hardest problem types in interviews, the business model is unlike any other industry. A single approved drug carries roughly $2.6B in average R&D cost over 12–15 years (DiMasi, 2016), much of it sunk in candidates that failed late-stage trials, and the winner earns back that spend inside a short window of market exclusivity before generics or biosimilars compress revenue. So the math is simple arithmetic; the difficulty is the judgment layer (value-based pricing, payer access, patent cliffs, and portfolio risk) that this guide walks through with a worked oncology example.

That context shapes every strategic decision. Here's how to navigate pharma cases.

The Pharma Business Model in 90 Seconds

If your target firms are L.E.K., ZS, Huron, IQVIA, or a dedicated biopharma practice, pair this guide with the broader life sciences consulting case interview guide. It connects drug launch, payer strategy, rNPV, and firm-specific expectations in one prep plan.

The pharma P&L is radically different from standard businesses:

One widely cited 2016 Tufts CSDD study estimated average approved drug development costs at approximately $2.6 billion, though estimates vary by methodology and therapeutic area. Once approved, a drug competes in a limited patent-protected window before generic or biosimilar competition can enter.

This explains why pharma drugs are expensive: revenue from successful drugs must also cover the cost of many candidates that fail during discovery or clinical trials.

The Pharma Case Framework (5 Dimensions)

Pharma Case Framework

1. 01

   1. Clinical Profile. What does the drug do? What condition does it treat? How does it compare to standard of care on efficacy and safety? What are the clinical data (Phase II/III results)?

2. 02

   2. Patient Population & Market Size. How many patients have this condition globally / in the target market? What % are diagnosed and treated? What is the peak sales opportunity?

3. 03

   3. Payer & Reimbursement Landscape. Which payers cover this condition? What are the formulary dynamics? Will payers reimburse at the proposed price? What is the access strategy?

4. 04

   4. Competitive Positioning & Pricing. What existing treatments exist? What is the clinical differentiation? What pricing approach applies (value-based, competitor-based)? What is the price range?

5. 05

   5. Launch Execution. What does the sales force look like? How do we reach key prescribers (KOLs)? What is the launch sequence (markets, timing)? What are the main launch risks?

Drug Launch Strategy Case

The most common pharma case type. The question: "Our client has received FDA approval for a new drug. What should the launch strategy look like?"

Worked Example: Oncology Drug Launch

Case prompt: Your client is a large pharma company that has just received FDA approval for a first-in-class cancer immunotherapy for non-small cell lung cancer (NSCLC). The drug shows a 40% relative improvement in overall survival versus the current standard of care. The client wants to know: what price should it charge, and how should it launch?

Step 1: Clinical profile and differentiation

• Indication: NSCLC (2nd largest cancer type; ~250,000 new US diagnoses/year)
• Clinical differentiation: 35% OS improvement vs. Keytruda's 25%, a 40% relative improvement over the comparator's improvement
• This is significant: Keytruda is a $20B+/year drug; a 40% relative improvement over its survival improvement is a major clinical advance

Step 2: Market sizing

• US NSCLC new cases: ~250,000/year
• % appropriate for immunotherapy (advanced/metastatic): ~40% = 100,000 patients
• Market penetration in Year 1 (new drug typically captures 5–15% in first year): ~8,000–15,000 patients

Step 3: Competitive pricing

A 35% vs. 25% improvement on a 12-month baseline gives an incremental 10 percentage points: (35% - 25%) × 12 months = 1.2 additional life-months, or 0.10 QALY at utility 1.0. At $150,000/QALY, the incremental value anchor is 0.10 × $150,000 = $15,000. A final price requires utility, comparator, payer, and access assumptions.

Illustrative price range: $190,000–$195,000/year, conditional on the stated assumptions. This range keeps the premium to approximately $10,000–$15,000 over Keytruda's $180,000/year price, within the $15,000 incremental value anchor. It is only a scenario if utility is 1.0, the $150,000/QALY threshold is applicable, the comparator remains Keytruda at the stated price, and payer access does not require additional rebates. Change any of those assumptions and the recommended price changes.

Step 4: Revenue potential

Year 3 peak penetration estimate (15% market share): 15,000 patients × $190,000 = $2.85B peak annual revenue

Step 5: Launch execution priorities

1. Payer access: Negotiate Tier 2 formulary placement with commercial insurers and obtain Medicare Part D coverage. Patient assistance program to reduce co-pays for uninsured/underinsured
2. KOL engagement: Target top 200 oncology thought leaders with Phase III data; fund medical education and conference presentations
3. Sales force: Deploy 300-person specialty oncology sales team focused on academic medical centers and cancer centers
4. Launch market sequence: US launch first (largest and fastest reimbursement); Europe in Year 2 (market access negotiations take 12–18 months per country)

Pipeline Valuation Case

The second most common pharma case type: should a pharma company acquire a biotech company with a promising drug in development?

The core framework: Risk-Adjusted NPV (rNPV)

Pipeline drugs are valued by adjusting their peak sales potential for:

• Probability of approval (success rate at each development stage)
• Time to peak sales (discounted cash flows)
• Development cost remaining

Simplified formula: rNPV = (Peak annual sales × Margin × Patent exclusivity years × Probability of approval) − Remaining development cost − Acquisition premium

Example calculation:

A biotech has a Phase II oncology drug:

• Peak annual sales potential if approved: $2B
• Probability of Phase III success and approval: ~20% (industry average for oncology)
• Patent exclusivity remaining at launch: 10 years
• Remaining development cost: $600M
• Estimated operating margin: 50%

A simplified interview approximation gives $1.4B before any premium. A 30% premium adds $420M, producing an illustrative $1.82B offer. A true rNPV requires time-phased cash flows, approval probabilities, development costs, launch timing, and a discount rate.

Market Access and Reimbursement

The "market access" question comes up in launch cases: how do we get payers to cover this drug?

The formulary tier system (US):

Oncology and rare disease drugs are typically on specialty tier, meaning patients pay 20–30% coinsurance. A $190,000 drug means roughly $38,000–$57,000 out-of-pocket annually. That's why patient assistance programs (co-pay cards, foundation grants) are essential launch components.

Key Pharma Terms for Interviews

Connecting to Firm-Specific Prep

Different firms weight pharma cases differently:

• ZS Associates: Heavy pharma/commercial analytics focus; expect quantitative pharma cases
• Simon-Kucher: Deep pricing strategy focus; pharma pricing cases are common
• L.E.K.: Pharma M&A and commercial due diligence; pipeline valuation cases

For a ranked overview of which firms specialize most heavily in life-sciences work, see the top pharma consulting firms guide. For the broader healthcare context, see healthcare case interview for coverage of hospitals, payers, and digital health cases. The life sciences consulting case interview guide goes deeper on FDA pathways and HEOR for biotech and MedTech. For pharma pricing strategy specifically, the pricing strategy case interview covers how to defend or justify price in the face of payer pressure and generic competition. The customer profitability case interview applies when the analysis requires segmenting by payer tier, formulary tier, or patient cohort. The ESG sustainability case interview is relevant for pharma clients facing environmental compliance, supply-chain sustainability, or ethical sourcing cases.

Sources and Further Reading (checked June 17, 2026)

• Management Consulted, Pharma Case Interview Example: managementconsulted.com/pharma-case-interview-example
• Tufts CSDD Drug Development Cost Study: csdd.tufts.edu/news/drug-development-cost-study
• McKinsey, GlobaPharm Practice Case: mckinsey.com/careers/interviewing/globapharm
• PrepLounge, McKinsey Pharma Pipeline Case: preplounge.com/en/management-consulting-cases/mckinsey-pharma-pipeline-291
• ZS Associates Practice Case: zs.com/careers/hiring-process/case-interview-practice/practice-case-two